AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03074435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Larvicide
Description: Larval breeding sites will be treated with larvicide
Study NCT03074435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BCC
Study NCT03074435 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ivermectin
Study NCT00783315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Call-Center Directed (CCD) Weight Loss Program
Description: This program will be implemented by trained counselors of Healthways, Inc., and will use telephone, Web, and e-mail contacts to engage participants. There will be no in-person visits.
Study NCT00783315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person Directed (IPD) Weight Loss Program
Description: This program will be primarily implemented through in-person visits (including group sessions) with health counselors at Johns Hopkins University. Telephone, Web, and e-mail contacts will occasionally be used.
Study NCT00783315 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Directed Weight Loss Program
Description: Participants will meet with study staff at the beginning of the study and will receive written information about weight loss.
Study NCT00895128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Starting dose of 100 mg taken by mouth 1 time a day every day for 28 day cycle or 50 mg for pediatric patients.
Study NCT00895128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Starting dose of 50 mg by mouth 1 or 2 times a day every day for 28 day cycle.
Study NCT00950040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention
Description: The intervention consists of educational information, aspects of motivational interviewing, feedback concerning alcohol use and measures of glycemic control, alcohol use monitoring, and formulation of a change plan.
Study NCT00950040 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General health education
Description: The intervention will consist of information about several general health behaviors.
Study NCT03467217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan potassium
Description: Losartan potassium is an angiotensin II receptor blocker acting on the AT 1 receptor subtype
Study NCT03467217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo losartan capsule
Description: Matching placebo losartan oral capsule
Study NCT00988897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEVACIZUMAB
Description: Pharmaceutical form: vials of 100mg/4mL or 400mg/16mL (25mg/mL) Route of administration: IV
Study NCT04236622 — intervention group
Intervention type: OTHER
Intervention: Periodontal clinical exam
Description: The individuals will be submitted to a complete periodontal examination, with measurements obtained at four points per tooth and dental implant (mesial, distal, buccal and lingual / palatal), in all teeth / implants present, except for the third molars, the parameters evaluated will be: Probing Depth, Clinical Insertion Level, Plaque Index, Teeth Bleeding Index. The implants will be evaluated according to the parameters: presence of suppuration, probing depth, bleeding to probing and presence of biofilm around the implants. To perform the clinical examinations, the following instruments will be required: Willians millimeter probe, exploratory probe and clinical mirror.~In all participants, complete periapical radiographic examinations with 14 radiographs will be performed to verify the bone cortical height level and to assist in the periodontal diagnosis.
Study NCT03041701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Once daily on days -7 through day 27 during cycle 1, and then days 0-27 for subsequent cycles.
Study NCT04505722 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Ad26.COV2.S will be administered at a single dose of 5\*10\^10 virus particles (vp) on Day 1 (or Month 6 for placebo recipients) and as a single booster dose at Year 1.
Study NCT04505722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo.
Study NCT02275780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doravirine
Description: Doravirine 100 mg tablet administered p.o. q.d.
Study NCT02275780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Doravirine 100 mg tablet administered p.o. q.d.
Study NCT02275780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: Darunavir 800 mg tablet administered p.o. q.d.
Study NCT02275780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: Ritonavir 100 mg tablet administered p.o. q.d.
Study NCT02275780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRUVADA™ or EPZICOM™/KIVEXA™
Description: The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate p.o. q.d. or EPZICOM™/KIVEXA™, a tablet containing 600 mg abacavir sulfate and 300 mg lamivudine, p.o. q.d.
Study NCT02275780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRUVADA™ or EPZICOM™/KIVEXA™
Description: The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate p.o. q.d. or EPZICOM™/KIVEXA™, a tablet containing 600 mg abacavir sulfate and 300 mg lamivudine, p.o. q.d.
Study NCT01619137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: water and soap
Description: water and soap for 6-8 hours per day.
Study NCT01619137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-iodine And normal salin treatment
Description: use of Povidone-iodine And normal salin treatment for irrigation of ununion laparatomy or episiotomy wound.
Study NCT02379351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-Home Non-Stress Test Device
Description: Airstrip® Sense4Baby™
Study NCT02441270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02441270 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Study NCT01393509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PU-H71
Description: PU-H71 will be administered as an intravenous infusion over 1 hour two times a week on a 2 week on and 1 week off (Q21 day) schedule with a starting dose of 10 mg/m2. A Cycle on study will be defined as 21 days. The same schedule of administration will be used for all patients in this Phase I trial, and a MCRM (modified continual reassessment method)design will be employed. The MPN expansion may explore different dosing schedules.
Study NCT01984892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: Cycle 1-Weeks 1 and 2: 1mg Poly-ICLC intratumoral (IT) injections (t=6) into same lesion over 2 weeks.~Weeks 3-9: 1mg Poly-ICLC 2x/week intramuscularly (IM) into thighs or upper arms.~Week 10: No treatment. CT scan of chest, abdomen, pelvis and extremities or neck; possible MRI brain scan.~Cycle 2-Weeks 11 and 12: 1mg Poly-ICLC IT injections (t=6) into same lesion over 2 weeks.~Weeks 13-19 - 1mg Poly-ICLC 2x/weekly IM in thighs or upper arms.~Weeks 20-26: no treatment. Week 26, evaluate response in absence of inflammation.~Maintenance - Weeks 27-36: For patients with stable disease or response; IM poly-ICLC injections; evaluation of clinical and immune response. Week 38 repeat tumor assessment, optional biopsy~Follow Up via phone every 3 months for 30months, after completion of treatments.
Study NCT03041701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Twice daily on days -7 through day 27 during cycle 1, and then days 0-27 for subsequent cycles.
Study NCT01625377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic Acid
Description: Dose of 1440 mg/day from transplantation to month 6 post- transplantation
Study NCT01625377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic Acid
Description: Dose of 1440 mg/day from transplantation to month 6 post- transplantation
Study NCT01625377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Administration of oral corticosteroid therapy was at the discretion of the centers according to their usual practice
Study NCT01625377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Administration of oral corticosteroid therapy was at the discretion of the centers according to their usual practice
Study NCT04392089 — intervention group
Intervention type: DEVICE
Intervention: Masimo, LidCO
Description: * Near-infrared spectroscopy (NIRS), pulse oxymetry (saturation), continous hemoglobine, peripheral perfusion index (PPI) as measured with Massimo~* Systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), stroke volume (SV), heart rate (HR), cardiac output (CO), systemic vascular resistance (SVR) as measured with LiDCO
Study NCT03581474 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bronchoscopic procedure
Description: Single-use flexible bronchoscope aScope 3 Large
Study NCT01626820 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluviral®
Description: 1 dose administered intramuscularly in deltoid region of non-dominant arm at Day 0
Study NCT04032873 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Monetary Cost of Immobilization Treatments
Description: Information regarding the monetary cost of casting and splinting patient's buckle fracture to be presented to adult subject/payer.
Study NCT04032873 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physician
Description: The monetary cost information is relayed by the patient's physician
Study NCT04032873 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Study Team
Description: The monetary cost information is relayed by a member of the study team
Study NCT04032873 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Before Initial Treatment Decision
Description: Monetary cost information is relayed during the initial consult, before the treatment decision is made.
Study NCT03385044 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MOVT
Description: ETT cuff will be inflated till the disappearance of audible air leak on auscultation, while abdominal carbon dioxide (CO2) inflation is maintained with peak inspiratory pressure of 25 cm H2O during volume controlled ventilation. The patient will be in the Trendelenburg position.
Study NCT03385044 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VE/VI ratio of Spirometer
Description: ETT cuff will be inflated till the VE/VI ratio meets the initial VE/VI ratio, while abdominal CO2 inflation is maintained with peak inspiratory pressure of 25 cm H2O during volume controlled ventilation. The patient will be in the Trendelenburg position.
Study NCT01803230 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02518724 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RIPC intervention exposure
Description: placing a sphygmomanometer on the non-dominant hand and applying pressure of 200 mmHg for 5 min followed by 5 min without pressure X 4 repeats
Study NCT02518724 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo intervention exposure
Description: placing a sphygmomanometer on the non-dominant hand and applying pressure of 100 mmHg for 5 min followed by 5 min without pressure X 4 repeats.
Study NCT00575068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDEC-114
Description: Phase 1-A Group 1 - 125 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 2 - 250 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 3 - 375 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-B Group 4 - 500 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase II-A \& II-B - Dosage start at the MTD (up to 375 mg/m2)
Study NCT02237339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Uric acid lowering medication.
Study NCT02237339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00240526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™ -B
Description: 3 (Groups A and C) or 4 (Groups B and D) intramuscular injections during the primary study
Study NCT00240526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B immunoglobulin (HBIg)
Description: 1 intramuscular injections at birth (primary study)
Study NCT01756560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethsone
Study NCT01756560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Study NCT01756560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study NCT01560260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01560260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linsitinib
Description: Given PO
Study NCT01560260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01837290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine infusion for premedication
Description: Group Dexmedetomidine (Group D): Midazolam 0.02 mg/kg + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30)
Study NCT01837290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: intravenous Midazolam 0.02 mg/kg for premedication
Study NCT01837290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: intravenous Midazolam 0.02 mg/kg for premedication
Study NCT01837290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline infusion
Description: Saline infusion to facilitate blinding
Study NCT01837290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Spinal block with hyperbaric bupivacaine 0.5% 12.5 mg
Description: Hyperbaric bupivacaine injection for spinal block
Study NCT01837290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal block with hyperbaric bupivacaine 0.5% 12.5 mg
Description: Hyperbaric bupivacaine injection for spinal block
Study NCT04353193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Terlipressin 1mg IV bolus
Study NCT04353193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Terlipressin by IV continuous infusion at a rate of 2mg/day (max 4mg/day) during 2 hours
Study NCT04353193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Octreotide 50mcg IV bolus plus continuous infusion at a rate of 50mcg/h during 2 hours
Study NCT02223117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thrombosomes
Description: Freeze-dried platelets
Study NCT02223117 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00125593 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Simvastatin 20 mg
Description: Once daily
Study NCT00125593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 20 mg
Description: Once daily
Study NCT00125593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10mg
Description: Once daily
Study NCT00125593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily
Study NCT02777996 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Computed Tomography
Description: Assessment protocol were adopted from the ELCAP study (modified) for Non Calcific Nodule with a diameter of less- equal than 5 mm at baseline and 3mm at repeated.
Study NCT02035813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib/Everolimus in combination with endocrine therapy
Study NCT02035813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Study NCT01743690 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotic lactobacilli reuteri
Study NCT01743690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nystatin
Study NCT01743690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nystatin
Study NCT01743690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluocinolone
Study NCT01743690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluocinolone
Study NCT03590665 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hand grip exercise and lower body negative pressure
Description: For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. If necessary, additional familiarization sessions will be scheduled for people with Down syndrome. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.
Study NCT01953770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-L-asparaginase ind
Description: 1,000 U/m2 on day 3 of induction therapy, intravenously, in 200 ml of saline, during 1 hour
Study NCT01953770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-L-asparaginase cons
Description: 1,000 U/m2 intravenously, in 200 ml of saline, during 1 hour, 24 hours after methotrexate on weeks 7, 9, and 11 - days 44, 58, and 72 (phase S1), weeks 15, 17, and 19 - days 100, 114, 128 (phase S2), weeks 23, 25, and 27 - days 156, 170, 184 (phase S3).
Study NCT01953770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E.coli L-asparaginase
Description: E.coli L-asparaginase (asparaginase medac) 5,000 U/m2 intramuscularly weekly, 24 hours after methotrexate dose, from week 7 to week 12 - days 44, 51, 58. 65, 72, 79 (phase S1), from week 15 to week 20 - days 100, 107, 114, 121, 128, 135 (phase S2), from week 23 to week 28 - days 156, 163, 170, 177, 184, 191 (phase S3).
Study NCT01953770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose Methotrexate
Description: 2,000 mg/m2 per 24 hours is given at days 43, 57, and 71 (weeks 7, 9, and 11). 1/5 of the total dose is given as slow intravenous bolus over 3-5 minutes. 4/5 of the total dose of methotrexate is injected as continuous 24 hours infusion.
Study NCT01953770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose Methotrexate
Description: 30 mg/м2 is given intramuscularly 1 time weekly - days 43, 50, 57, 64, 71, and 78 (weeks 7, 8, 9, 10, 11, and 12).
Study NCT01953770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple intrathecal therapy
Description: Intrathecal injection of 3 drugs is additionally given three times during phase S-2 (weeks 15, 17, and 19 - days 99, 113, and 127), and three times during phase S-3 (weeks 23, 25, and 27 - days 155, 169, and 183).
Study NCT01953770 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Cranial irradiation
Description: 12 Gy cranial irradiation is conducted at weeks 31-32 of the Protocol in patients >3 years of age
Study NCT01953770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Daunorubicin at a dose of 45 mg/m2 i.v. for 6 hours on day 8 of induction therapy
Study NCT01953770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: Daunorubicin at a dose of 45 mg/m2 i.v. for 6 hours on day 8 of induction therapy
Study NCT00406419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate tablet was administered orally at a dose 7.5-25 mg
Study NCT00406419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate tablet was administered orally at a dose 7.5-25 mg
Study NCT00406419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocrelizumab
Description: Ocrelizumab was administered via IV infusion at a dose specified in arm description
Study NCT00406419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ocrelizumab
Description: Ocrelizumab was administered via IV infusion at a dose specified in arm description
Study NCT00406419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to ocrelizumab was administered via IV infusion
Study NCT02104635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delivery of a Post-Partum Package
Study NCT03632434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: tDCS generates a small electric current which modulates how easy it is for active brain cells to discharge. The device is a neoprene cap worn over the head, and in the cap there are two electrodes, which are small metal discs, where the current comes from.